{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05419492",
            "orgStudyIdInfo": {
                "id": "ETX-DS-002"
            },
            "organization": {
                "fullName": "Encoded Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome",
            "officialTitle": "ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome",
            "acronym": "ENDEAVOR",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "a-clinical-study-to-evaluate-the-safety-and-efficacy-of-in-infants-and-children-with-positive-dravet-syndrome"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-06-10",
            "studyFirstSubmitQcDate": "2022-06-10",
            "studyFirstPostDateStruct": {
                "date": "2022-06-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Encoded Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to \\<36 months. Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study."
        },
        "conditionsModule": {
            "conditions": [
                "Dravet Syndrome"
            ],
            "keywords": [
                "Dravet",
                "SCN1A",
                "DEE",
                "developmental and epileptic encephalopathy",
                "Dravet Syndrome",
                "SCN1A-positive",
                "SCN1A+"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Part 1 is open-label with no blinding.\n\nPart 2 will be conducted in a double-blinded manner whereby all Primary Site Staff (including clinicians, research coordinators, neuropsychologists, and physical therapists), study participants and caregivers, Sponsor and Sponsor-designees will be blinded through the end of Week 52 following Day 1 for a given participant. The Surgical Site Staff and Pharmacists will be unblinded to treatment assignment",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 22,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1 will follow an open-label, rule-based, dose-escalation design and will initially evaluate 2 dose levels of ETX101 in approximately 4 participants.",
                    "interventionNames": [
                        "Drug: ETX101"
                    ]
                },
                {
                    "label": "Part 2",
                    "type": "SHAM_COMPARATOR",
                    "description": "Part 2 is a dose-selection study, which will follow a double-blind (up through Week 52), randomized, sham delayed-treatment control design in approximately 18 participants.\n\nThere will be up to 3 cohorts in Part 2. Participants will be randomized 1:1:1 to study treatment (ie, Dose Level 1 or Dose Level 2) or sham procedure with delayed treatment. At the conclusion of Part 1, if the recommendation is made to proceed with a single dose level of ETX101 in Part 2, participants will be randomized 1:1 to study treatment or sham procedure with delayed treatment.",
                    "interventionNames": [
                        "Drug: ETX101"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ETX101",
                    "description": "ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.",
                    "armGroupLabels": [
                        "Part 1",
                        "Part 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportions of participants experiencing any treatment-emergent adverse events (AEs), serious adverse events (SAEs), related AEs, AEs with severity Grade \u2265 3, AEs resulting in study discontinuation, and AEs with a fatal outcome.",
                    "timeFrame": "Day 1 through Study Completion"
                },
                {
                    "measure": "Percent change in monthly countable seizure frequency (MCSF) period, with countable seizures defined as generalized tonic-clonic/clonic, focal motor with clearly observable clinical signs, tonic, or atonic seizures.",
                    "timeFrame": "Between the 8-week baseline period (prior to Day 1) and the 48-week post dosing period (defined as Week 5 through Week 52)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of participants with \u2265 90% reduction in monthly countable seizure frequency (MCSF).",
                    "timeFrame": "Between the 8-week baseline period (prior to Day 1) and the 48-week post dosing period (defined as Week 5 through Week 52)."
                },
                {
                    "measure": "Change from baseline in the Vineland-3 Expressive Communication raw score at Week 52",
                    "timeFrame": "Baseline through Week 52"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must have a predicted loss of function pathogenic or likely pathogenic SCN1A variant.\n* Participant must have experienced their first convulsive seizure between the ages of 3 and 15 months.\n* Participant must have a clinical diagnosis of Dravet syndrome or the treating clinician must have a high clinical suspicion of a diagnosis of Dravet syndrome.\n* Participant is receiving at least one prophylactic antiseizure medication.\n\nExclusion Criteria:\n\n* Participant has another genetic mutation or clinical comorbidity which could potentially confound the typical Dravet phenotype.\n* Participant has a known central nervous system structural and/or vascular abnormality (indicated by an MRI or CT scan of the brain).\n* Participant has an abnormality that may interfere with CSF distribution and/or has an existing ventriculoperitoneal shunt.\n* Participant is currently taking or has taken antiseizure medications (ASMs) at a therapeutic dose that are contraindicated in Dravet syndrome, including sodium channel blockers.\n* Participant has experienced seizure freedom for a period of 4 consecutive weeks within the 90-day period prior to informed consent.\n* Participant has previously received gene or cell therapy.\n* Participant is currently enrolled in a clinical trial or receiving an investigational therapy, including under an expanded access and/or compassionate use program.\n* Participant has clinically significant underlying liver disease.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Months",
            "maximumAge": "35 Months",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Encoded Patient Advocacy",
                    "role": "CONTACT",
                    "phone": "+1 (650) 398-4301",
                    "email": "patientadvocacy@encoded.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Salvador Rico, M.D., Ph.D",
                    "affiliation": "Encoded Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCSF Benioff Children's Hospitals",
                    "status": "NOT_YET_RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Sullivan, MD",
                            "role": "CONTACT",
                            "email": "joseph.sullivan@ucsf.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Cook Children's Medical Center",
                    "status": "RECRUITING",
                    "city": "Fort Worth",
                    "state": "Texas",
                    "zip": "76104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dianna Grado, RN, CCRC",
                            "role": "CONTACT",
                            "phone": "682-885-2844",
                            "email": "Dianna.Grado@cookchildrens.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.72541,
                        "lon": -97.32085
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004831",
                    "term": "Epilepsies, Myoclonic"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000004829",
                    "term": "Epilepsy, Generalized"
                },
                {
                    "id": "D000004827",
                    "term": "Epilepsy"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000073376",
                    "term": "Epileptic Syndromes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7983",
                    "name": "Epilepsy",
                    "relevance": "LOW"
                },
                {
                    "id": "M7987",
                    "name": "Epilepsies, Myoclonic",
                    "asFound": "Dravet Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7985",
                    "name": "Epilepsy, Generalized",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M1165",
                    "name": "Epileptic Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1938",
                    "name": "Dravet Syndrome",
                    "asFound": "Dravet Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1024",
                    "name": "CDKL5 Deficiency Disorder",
                    "asFound": "Dravet Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}